Paola Zaratin1, Brenda Banwell2, Timothy Coetzee3, Giancarlo Comi4, Anthony Feinstein5, Robert Hyde6, Marco Salvetti7, Kathryn Smith8. 1. Italian Multiple Sclerosis Foundation, Genoa, Italy. 2. Division of Child Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 3. National Multiple Sclerosis Society, New York, NY, USA. 4. Università Vita Salute San Raffaele, Milan, Italy. 5. Sunnybrook Research Institute and University of Toronto, Toronto, Canada. 6. Biogen International GMBH, International Progressive MS Alliance Industry Forum representative, Zürich, Switzerland. 7. Department of Neurosciences, Mental Health and Sensory Organs, Centre for Experimental Neurological Therapies (CENTERS), Sapienza University of Rome, Rome, Italy. 8. International Progressive MS Alliance, Lyme, CT, USA.
Abstract
Background: The COVID-19 pandemic has reinforced the importance of research for the health of our society and highlighted the need for stakeholders of the health research and care continuum to form a collaborative and interdependent ecosystem. Objective: With the world still reeling from waves of the COVID-19 pandemic and adapting to the vaccine rollout at widely different rates, the International Progressive MS Alliance (hereafter Alliance) organized a meeting (April 2021) to consider how the Covid-19 pandemic impacts the health and well-being of people with progressive Multiple Sclerosis (MS). Methods: We invited the Alliance stakeholders and experts to present what they have learned about SARS-CoV-2 infection and progressive MS and to define future scientific priorities. Results: The meeting highlighted three priorities for additional focus: (1) the impact of Disease Modifying Therapies (DMTs) on the risk of COVID-19 and on the efficacy of COVID-19 vaccines in people with progressive MS; (2) the long-term impact of COVID-19 and COVID-19 vaccines on the biology of progressive MS; and (3) the impact on well-being of people with progressive MS. Conclusion: This paper's calls to action could represent a path toward a shared research agenda. Multi-stakeholder and long-term investigations will be required to drive and evolve such an agenda.
Background: The COVID-19 pandemic has reinforced the importance of research for the health of our society and highlighted the need for stakeholders of the health research and care continuum to form a collaborative and interdependent ecosystem. Objective: With the world still reeling from waves of the COVID-19 pandemic and adapting to the vaccine rollout at widely different rates, the International Progressive MS Alliance (hereafter Alliance) organized a meeting (April 2021) to consider how the Covid-19 pandemic impacts the health and well-being of people with progressive Multiple Sclerosis (MS). Methods: We invited the Alliance stakeholders and experts to present what they have learned about SARS-CoV-2 infection and progressive MS and to define future scientific priorities. Results: The meeting highlighted three priorities for additional focus: (1) the impact of Disease Modifying Therapies (DMTs) on the risk of COVID-19 and on the efficacy of COVID-19 vaccines in people with progressive MS; (2) the long-term impact of COVID-19 and COVID-19 vaccines on the biology of progressive MS; and (3) the impact on well-being of people with progressive MS. Conclusion: This paper's calls to action could represent a path toward a shared research agenda. Multi-stakeholder and long-term investigations will be required to drive and evolve such an agenda.
Authors: Tommaso Manacorda; Paolo Bandiera; Federica Terzuoli; Michela Ponzio; Giampaolo Brichetto; Paola Zaratin; Daiana Bezzini; Mario A Battaglia Journal: J Health Serv Res Policy Date: 2020-12-18
Authors: Liesbet M Peeters; Tina Parciak; Clare Walton; Lotte Geys; Yves Moreau; Edward De Brouwer; Daniele Raimondi; Ashkan Pirmani; Tomas Kalincik; Gilles Edan; Steve Simpson-Yap; Luc De Raedt; Yann Dauxais; Clément Gautrais; Paulo R Rodrigues; Landon McKenna; Nikola Lazovski; Jan Hillert; Lars Forsberg; Tim Spelman; Robert McBurney; Hollie Schmidt; Arnfin Bergmann; Stefan Braune; Alexander Stahmann; Rodden Middleton; Amber Salter; Bruce F Bebo; Juan I Rojas; Anneke van der Walt; Helmut Butzkueven; Ingrid van der Mei; Rumen Ivanov; Kerstin Hellwig; Guilherme Sciascia do Olival; Jeffrey A Cohen; Wim Van Hecke; Ruth Dobson; Melinda Magyari; Doralina Guimarães Brum; Ricardo Alonso; Richard Nicholas; Johana Bauer; Anibal Chertcoff; Jérôme de Sèze; Céline Louapre; Giancarlo Comi; Nick Rijke Journal: Mult Scler Date: 2020-07-14 Impact factor: 6.312
Authors: João J Cerqueira; Ana F Ladeira; Ana M Silva; Ângela Timóteo; José Vale; Lívia Sousa; Marta Arenga; Pedro Abreu; Rui Guerreiro; João de Sá Journal: Front Neurol Date: 2021-03-08 Impact factor: 4.003
Authors: Clare Walton; Rachel King; Lindsay Rechtman; Wendy Kaye; Emmanuelle Leray; Ruth Ann Marrie; Neil Robertson; Nicholas La Rocca; Bernard Uitdehaag; Ingrid van der Mei; Mitchell Wallin; Anne Helme; Ceri Angood Napier; Nick Rijke; Peer Baneke Journal: Mult Scler Date: 2020-11-11 Impact factor: 6.312
Authors: Saúl Reyes; Anthony L Cunningham; Tomas Kalincik; Eva Kubala Havrdová; Noriko Isobe; Julia Pakpoor; Laura Airas; Reem F Bunyan; Anneke van der Walt; Jiwon Oh; Joela Mathews; Farrah J Mateen; Gavin Giovannoni Journal: J Neuroimmunol Date: 2021-06-07 Impact factor: 3.478